The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas

European Journal of Haematology

Volumn 86, Issue 6, 2011, Pages 466-476

  Rayman, Nazik ^a   Lam, King H ^a   van der Holt, Bronno ^a   Koss, Clara ^a   van Leeuwen, Joost ^a   Budel, Leo M ^b   Mulder, Andries H ^c   Sonneveld, Pieter ^a   Delwel, Ruud ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

^c RIJNSTATE HOSPITAL   (Netherlands)

Author keywords

Cannabinoid receptor type 2; Diffuse large B cell lymphoma; Prognosis; Protein expression

Indexed keywords

CANNABINOID 2 RECEPTOR; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; INTERFERON REGULATORY FACTOR 4; METHOTREXATE; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALGORITHM; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; RECEPTOR, CANNABINOID, CB2; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79955980905     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01596.x     Document Type: Article

References (49)

1. Lynn AB, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994;268:1612-23.
2. Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, Le Fur G, Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993;214:173-80.
3. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire M, Le Fur G, Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995;232:54-61.
4. Bouaboula M, Dussossoy D, Casellas P. Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 1999;274:20397-405.
5. Carayon P, Marchand J, Dussossoy D, et al. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood 1998;92:3605-15.
6. Rayman N, Lam KH, Laman JD, Simons PJ, Löwenberg B, Sonneveld P, Delwel R. Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. J Immunol 2004;172:2111-7.
7. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.
8. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-5.
9. Valk PJ, Delwel R. The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. Leuk Lymphoma 1998;32:29-43.
10. Alberich Jordà M, Rayman N, Tas M, Verbakel SE, Battista N, van Lom K, Löwenberg B, Maccarrone M, Delwel R. The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. Blood 2004;15:104.
11. Rayman N, Lam KH, van Leeuwen J, Mulder AH, Budel LM, Löwenberg B, Sonneveld P, Delwel R. The expression of the Peripheral Cannabinoid Receptor on cells of the immune system and Non-Hodgkin's lymphomas. Leuk Lymphoma 2007;48:1389-99.
12. Gustafsson K, Wang X, Severea D, Eriksson M, Eriksson M, Kimby E, Merup M, Christensson B, Flygare J, Sander B. Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 2008;123:1025-33.
13. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC, France, 2008.
14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
15. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large b-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26.
16. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-Cell lymphoma. J Clin Oncol 2006;24:3121-7.
17. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
18. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
19. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
20. Sonneveld P, van Putten W, Holte H, et al. Intensified CHOP with rituximab for intermediate or high-risk non-Hodgkin's lymphoma: interim analysis of a randomized phase III trial in elderly patients by the Dutch HOVON and Nordic Lymphoma Groups. Blood (ASH Annual Meeting Abstracts) 2005;106:116.
21. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-50.
22. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
23. Verdonck LF, Notenboom A, de Jong DD, MacKenzie MA, Verhoef GE, Kramer MH, Ossenkoppele GJ, Doorduijn JK, Sonneveld P, van Imhoff GW. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodkin Lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 2007;109:2759-66.
24. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
25. Fu K, Weisenburger DD, Choi WW, et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587-94.
26. van Imhoff GW, Boerma E-JG, van der Holt B, Schuuring E, Verdonck LF, Kluin-Nelemans HC, Kluin PM. Prognostic impact of the germinal center-associated proteins and chromosomal breakpoints in poor-risk DLBCL. J Clin Oncol 2006;24:4135-42.
27. Sjo LD, Poulsen CB, Hansen M, Moller MB, Moller MB, Ralfkaer E. Profiling of diffuse large b-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol 2007;79:501-7.
28. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De Wolf-Peeters C. Large cleaved immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005;28:7060-8.
29. Muris JJF, Meijer CJLM, Vos W, van Krieken JHJM, Jiwa NM, Ossenkoppele GJ, Oudejans JJJ. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006;208:714-23.
30. Veeleken H, Dannheim S, Schulte Moenting J, Martens UM, Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol 2007;18:931-9.
31. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, Blomqvist C, Enblad G, Leppä S. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930-5.
32. Barrans S, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP, Morgan GJ, Jack AS. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;15:1136-43.
33. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
34. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-24.
35. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
36. Rimsza LM, LeBlanc ML, Joseph M, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112:3425-33.
37. Tagawa H, Suguro M, Tsuzuki S, Matsuo K, Karnan S, Ohshima K, Okamoto M, Morishima Y, Nakamura S, Seto M. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005;1:1770-7.
38. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, Filippa DA, Nimer SD, Teruya-Feldstein J. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol 2002;33:968-74.
39. Seglison D. The tissue micro-array as a translational research tool for biomarker profiling and validation. Biomarkers 2005;10(Supp 1):S77-82.
40. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686-94.
41. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B, Kajdacsy-Balla A, Perkins SL. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004;28:464-70.
42. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martínez A, Bosch F, Colomer D, Falini B, Montserrat E, Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78-84.
43. Biasoli I, Morais JC, Scheliga A, Milito CB, Romano S, Land M, Pulcheri W, Spector N. CD10 and BCL-2 expression combined with the IPI can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. Histopathology 2005;46:328-33.
44. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
45. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
46. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
47. Jordà MA, Lowenberg B, Delwel R. The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. Blood 2003;101:1336-43.
48. de Jong D, Rosenwald A, Chanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805-12.
49. Rayman N, Lam KH, Koss C, et al. Prognostic assessment of immunohistochemical GCB and ABC type Diffuse Large B-cell Lymphoma's treated with CHOP in two prospective clinical trials. Submitted 2010.